Journal article
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
- Abstract:
-
Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy but there are no efficacy data for the leading candidate vaccine being considered for widespread use. To address this knowledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 419.4KB)
-
- Publisher copy:
- 10.1016/s0140-6736(17)32149-9
Authors
Funding
Wellcome Trust
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Journal website
- Volume:
- 390
- Issue:
- 10111
- Pages:
- 2472-2480
- Publication date:
- 2017-09-28
- Acceptance date:
- 2017-07-26
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Pmid:
-
28965718
- Source identifiers:
-
732517
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:732517
- UUID:
-
uuid:3505598d-8d76-4c86-9edd-da7959f9ef81
- Local pid:
- pubs:732517
- Deposit date:
- 2017-10-06
Terms of use
- Copyright holder:
- © 2017 Jin, et al Published by Elsevier Ltd
- Copyright date:
- 2017
- Notes:
- This is an open access article published under a creative commons licence, see: https://creativecommons.org/licenses/by/4.0/
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record